TY - JOUR
T1 - Scalpel or SABR for treatment of early-stage lung cancer
T2 - Clinical considerations for the multidisciplinary team
AU - Shirvani, Shervin M.
AU - Chang, Joe Y.
PY - 2011/9
Y1 - 2011/9
N2 - Treatment options for early-stage (T1-2 N0) non-small cell lung cancer are often limited by the patient's advanced age, poor performance status, and comorbidities. Despite these challenges, stereotactic ablative radiotherapy (SABR) provides a highly effective and safe therapy for intrathoracic tumors and has become the standard of care for delivering definitive treatment in medically inoperable patients. High-quality treatment, which includes reliable immobilization, accurate tumor targeting, and precise verification of dose delivery, is essential both to achieve successful cure and to avoid debilitating toxicities. Generally, SABR is well tolerated in patients with peripherally located tumors, but even centrally or superiorly located lesions can be treated if there is adequate conformal avoidance of normal structures and/or modified fractionation to meet dose constraints. While several preliminary studies suggest that SABR is as efficacious as surgery in operable patients, results of randomized data will illuminate whether the indications for SABR can be expanded to include patients who are candidates for surgical resection. Herein, we review the rationale for using SABR and its application in treating different patient populations with early-stage lung cancer.
AB - Treatment options for early-stage (T1-2 N0) non-small cell lung cancer are often limited by the patient's advanced age, poor performance status, and comorbidities. Despite these challenges, stereotactic ablative radiotherapy (SABR) provides a highly effective and safe therapy for intrathoracic tumors and has become the standard of care for delivering definitive treatment in medically inoperable patients. High-quality treatment, which includes reliable immobilization, accurate tumor targeting, and precise verification of dose delivery, is essential both to achieve successful cure and to avoid debilitating toxicities. Generally, SABR is well tolerated in patients with peripherally located tumors, but even centrally or superiorly located lesions can be treated if there is adequate conformal avoidance of normal structures and/or modified fractionation to meet dose constraints. While several preliminary studies suggest that SABR is as efficacious as surgery in operable patients, results of randomized data will illuminate whether the indications for SABR can be expanded to include patients who are candidates for surgical resection. Herein, we review the rationale for using SABR and its application in treating different patient populations with early-stage lung cancer.
KW - Early-stage non-small cell lung cancer
KW - Stereotactic ablative body radiotherapy
KW - Stereotactic body radiation therapy
UR - http://www.scopus.com/inward/record.url?scp=80053219245&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053219245&partnerID=8YFLogxK
U2 - 10.3390/cancers3033432
DO - 10.3390/cancers3033432
M3 - Review article
C2 - 24212962
AN - SCOPUS:80053219245
SN - 2072-6694
VL - 3
SP - 3432
EP - 3448
JO - Cancers
JF - Cancers
IS - 3
ER -